EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Aesthetic Improvements Over Time: Long‐Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines

Tatjana Pavicic iD, Cheryl Burgess, Sabrina Fabi iD, Mark S Nestor iD, Eva Kristina Bee, Matthias Imhof, Hanna Dersch iD, Vladimir Sudimac

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70460 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Tatjana Pavicic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice for Dermatology & Aesthetics Dr. Tatjana Pavicic, Munich, Germany. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents, Cosmetic Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Two Phase III randomized controlled trials were conducted in the US (ULTRA I) and Germany (ULTRA II) to investigate the efficacy of incobotulinumtoxinA for simultaneous treatment of upper facial lines (UFLs: glabellar frown lines [GFLs], horizontal forehead lines [HFLs] and lateral canthal lines [LCLs]). Patients/Methods Healthy adults with moderate to severe GFLs, HFLs, and symmetrical LCLs were enrolled. Participants were randomized 2:1:1 to three groups: placebo, UFLs, and GFLs & HFLs (ULTRA I) or LCLs (ULTRA II). All participants received up to 64 units of incobotulinumtoxinA in the main period (MP) and were eligible for two additional treatment cycles in the open‐label extensions (OLEX). Endpoints included participant‐ and investigator‐assessed Global Aesthetic Improvement Scale (pGAIS and iGAIS, respectively; any improvement defined as ≥ +1 score versus baseline) and the percentage of GFL, HFL, and LCL responders, defined as ≥ 1‐grade improvement in Merz Aesthetics Scale (MAS) score versus baseline at maximum contraction.

Results

For pGAIS at Day 30, the proportion of participants with any improvement was very high (> 97%) across all three treatment cycles. iGAIS results were similar and slightly higher than pGAIS results. In the MP, investigator and participant MAS assessments were similar, with > 78% of participants showing a positive treatment response for UFLs up to Day 90; responses in the placebo groups remained low at all time points (< 13%). MAS results in the OLEX were consistent with the MP.

Conclusions

Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. Trial Registration ULTRA I: NCT04594213; ULTRA II: NCT04622254

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ASkin AgingNeuromuscular AgentsCosmetic TechniquesHumansFemaleAdultMaleTreatment OutcomeMiddle AgedEstheticsForeheadTime FactorsDouble-Blind Method

Stichwörter der Autor:innen

BoNT‐AXeominaestheticsforeheadincobotulinumtoxinAupper facial lines

Substanzen

Botulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agents

Autor:innen und Institutionen

  • Private Practice for Dermatology & Aesthetics Dr. Tatjana Pavicic, Munich, Germany.
  • Center for Dermatology and Dermatologic Surgery, Washington, DC, USA.
  • Cosmetic Laser Dermatology, San Diego, California, USA.
  • Center for Clinical and Cosmetic Research, Aventura, Florida, USA.
  • Department of Dermatology and Cutaneous Surgery, Division of Plastic Surgery, Department of Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Practice for Aesthetic Dermatology, Drensteinfurt, Germany.

ORCID-Profile: Tatjana Pavicic, Sabrina Fabi, Mark S Nestor, Hanna Dersch

Zitieren

APA

Pavicic, T., Burgess, C., Fabi, S., Nestor, M. S., Bee, E. K., Imhof, M., Dersch, H., & Sudimac, V. (2025). Aesthetic Improvements Over Time: Long‐Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70460

Vancouver

Pavicic T, Burgess C, Fabi S, Nestor MS, Bee EK, Imhof M, et al. Aesthetic Improvements Over Time: Long‐Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70460

BibTeX
@article{Pavicic2025,
  author = {Pavicic, Tatjana and Burgess, Cheryl and Fabi, Sabrina and Nestor, Mark S and Bee, Eva Kristina and Imhof, Matthias and Dersch, Hanna and Sudimac, Vladimir},
  title = {Aesthetic Improvements Over Time: Long‐Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70460}
}
Kostenlos starten →